Company Overview
Snapshot
Founded in March 2006 by Avi Lazar, PulmOne operates with 51–200 employees. The company has raised $13.71M across 5 funding rounds from 2 investors. In December 2021, PulmOne received funding from Alpha LTI and OurCrowd.
Business overview
PulmOne is a Health Tech & Life Sciences company focused on developing patient-friendly, accurate, and cost-effective devices for pulmonary function testing. Its core product, the MiniBox, is a desktop system designed for measuring lung volume and spirometry without relying on a plethysmograph or external gas source. The MiniBox+ extends this capability by adding a diffusing capacity (DLCO) module, offering a complete solution for diagnosing, treating, and monitoring respiratory diseases. PulmOne serves healthcare providers, hospitals, and clinics in the medical devices and diagnostics sectors, with a presence in geomarkets including Europe, the United States, and Japan.
Strategic signal
In November 2019, PulmOne expanded its product offering by integrating FeNO by NIOX® with its MiniBox+™ Complete Pulmonary Function Testing System. This strategic move enhances the diagnostic capabilities of PulmOne's devices, providing a more comprehensive solution for respiratory disease assessment. For investors, this signals the company's commitment to continuous product development and market expansion through partnerships, aiming to capture a larger share of the pulmonary diagnostics market.
Log in to access full profile ›Company Intelligence Q&A
- What is PulmOne's primary product?
- PulmOne's primary product is the MiniBox, a desktop device for measuring lung volume and spirometry. The MiniBox+ offers an enhanced version with a diffusing capacity (DLCO) module for a complete pulmonary function testing solution.
- When was PulmOne founded and by whom?
- PulmOne was founded in March 2006 by Avi Lazar.
- What significant product enhancement did PulmOne announce in late 2019?
- In November 2019, PulmOne announced that it was offering FeNO by NIOX® with its MiniBox+™ Complete Pulmonary Function Testing System, expanding its diagnostic capabilities.
- Which investors participated in PulmOne's December 2021 funding round?
- This round was a Convertible Debt funding type.
- What regulatory clearances has PulmOne received for its products?
- PulmOne has received FDA 510k clearance and a CE mark for its first product, enabling sales in several locations.